DSMB Meeting Minutes (Summary) — GLPI103-301
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Summary minutes of a DSMB meeting.
Why it exists. The DSMB's reviews and recommendations must be documented. The minutes record what safety data were reviewed and the board's recommendation (typically to continue as planned), forming part of the trial's safety audit trail.
How it is produced here. It is an operational trial document — a plan, charter, or template of the kind kept in the Trial Master File. It describes how the trial is run, rather than reporting the trial's results.
Format & governing standard. per DSMB Charter (TMF-DSMB)
DSMB Meeting Minutes (Summary) — GLPI103-301
| Field | Value |
|---|---|
| Document ID | TMF-DSMB-MIN |
| Study No. | GLPI103-301 |
| Standard | per DSMB Charter (TMF-DSMB) |
| Confidentiality | Confidential — TMF (closed-session content restricted) |
Illustrative
[MOCK]open-session summaries of DSMB safety reviews. Safety figures are consistent with the final dataset (CSR-301 §12;outputs/). Closed-session unblinded detail is restricted.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | DSMB Secretariat | Initial minutes summary |
Meeting 0 — Organizational [MOCK]
Reviewed and adopted the Charter; confirmed independence/quorum; agreed data presentation format, AESI definitions, and meeting milestones (~25/50/75% enrolled).
Meeting 1 — Safety Review (≈25% enrolled) [MOCK]
- Data reviewed: disposition, TEAEs by arm, AESIs, SAEs, hypoglycaemia, labs.
- Findings: gastrointestinal AEs predominant and as expected for the class; isolated serious events reviewed, none treatment-related; no pancreatitis or thyroid events; hypoglycaemia infrequent.
- Recommendation: CONTINUE without modification.
Meeting 2 — Safety Review (≈50% enrolled) [MOCK]
- Gastrointestinal AEs as expected for the class and broadly balanced across arms; predominantly mild–moderate; manageable with titration; discontinuations within expected range.
- No new safety signal; cardiovascular/heart-rate parameters unremarkable.
- Recommendation: CONTINUE; reinforce titration guidance in site communications.
Meeting 3 — Safety Review (≈75% enrolled) [MOCK]
- Cumulative safety consistent with the class profile; serious events reviewed, none treatment-related; AESIs stable.
- Recommendation: CONTINUE to completion.
Final-database safety (CSR-301): Any TEAE 67.1/67.7/72.2%; nausea IV 32.3% vs sema 21.4% (ns); 10 serious adverse events and 2 deaths (none treatment-related) — consistent with the DSMB's interim assessments.
Comments (0)
No comments yet. Be the first to say something!